PSA (Prostate Specific Antigen), Total (Offer)

The PSA (Prostate Specific Antigen), Total (Offer) test is a blood test that measures the level of Prostate Specific Antigen (PSA), a protein produced by the prostate gland. PSA is normally present in small amounts in the bloodstream, but elevated levels may indicate prostate disorders such as prostate cancer, benign prostatic hyperplasia (BPH), or prostatitis. The Total PSA test is widely used to screen for prostate-related conditions, assess prostate health, and monitor patients undergoing treatment for prostate disease.

The Total PSA test is commonly recommended for men aged 50 years and above, or earlier for those with a family history or increased risk of prostate cancer. It is also advised for individuals experiencing symptoms such as difficulty in urination, frequent urination, weak urine flow, painful urination, or blood in the urine. While elevated PSA levels may raise suspicion of prostate cancer, they can also occur due to benign prostate enlargement, prostatitis, recent urinary procedures, or other non-cancerous conditions. Therefore, the PSA test is not a standalone diagnostic test and should always be interpreted together with the patient’s symptoms, digital rectal examination (DRE), imaging studies, and, when necessary, a prostate biopsy. Early detection through PSA screening can help identify prostate disease at an earlier stage and improve treatment outcomes.